Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities

In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer Vol. 129; no. 6; pp. 897 - 899
Main Authors: Machado, Nicole D, Heather, Lisa C, Harris, Adrian L, Higgins, Geoff S
Format: Journal Article
Language:English
Published: England Nature Publishing Group 05.10.2023
Subjects:
Clinical trials
Electron transport chain
Humans
Inhibitor drugs
Medical research
Mitochondria - metabolism
Oxidative Phosphorylation
Phosphorylation
Targeted cancer therapy
Toxicity
ISSN:0007-0920, 1532-1827, 1532-1827
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity and toxicity demonstrate what lessons can be learned from this failure and where new opportunities lie.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-023-02394-9